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I N T R O D U C T I O N
Cardiovascular diseases (CVD) are the leading cause of
mortality and admission in hospital for women, account-
ing for a third of all deaths of women worldwide and half
of all deaths of women over 50 years of age in
developing countries [1,2]. By contrast, breast cancer
accounts for just 3% of all deaths in the female adult
population [3].
Recent advances in the field of cardiovascular medi-
cine have not led to significant drops in case fatality rates
for women, compared to the dramatic reductions
achieved for men [4]. Such gender-specific difference in
CVD mortality provides additional support for a lack of
comparable progress in population-based risk reduction
efforts for women [2] and is probably related to a
knowledge gap about CVD in women.
In this context, several evidences demonstrated signif-
icant delays in health care–seeking behaviour, less
intensive resource use patterns and longer diagnosis
times for women than men. In this context, women are
less likely to be referred for coronary angiography and
revascularization procedures than men, and referral
tends to occur at a later stage in the disease process [5].
Although a lower intensity of care may be, in part,
related to a differential clinical history, symptoms profile
and acuity of presentation, under-recognition of a
cardiovascular involvement in women by caregivers
may also be contributory to worsening outcome, espe-
cially in women with an established diagnosis of
ischaemic heart disease or myocardial infarction [6].
Moreover, pharmacological therapy is hampered by
defective evidence, as women are frequently underrep-
resented in clinical trials and there may be gender
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A B S T R A C T
More than a quarter of a million women die each year in the industrialized countries
from cardiovascular diseases (CVD), and current projections indicate that this
number will continue to rise with our ageing population. Important sex-related
differences in the prevalence, presentation, management and outcomes of different
CVD have discovered in the last two decades of cardiovascular research. Nevertheless,
much evidence supporting contemporary recommendations for testing, prevention
and treatment of CVD in women is still extrapolated from studies conducted
predominantly in men. The compendium of CVD indicates that current research and
strategy development must focus on gender-specific issues to address the societal
burden and costs related to these incremental shifts in female gender involvement.
Indeed, this significant burden of CVD in women places unique diagnostic, treatment
and financial encumbrances on our society that are only further intensified by a lack
of public awareness about the disease on the part of patients and clinicians alike. This
societal burden of the disease is, in part, related to our poor understanding of gender-
specific pathophysiologic differences in the presentation and prognosis of CVD and the
paucity of diagnostic and treatment guidelines tailored to phenotypic differences in
women. In this, scenario is of outmost importance to know these differences to
provide the best care for female patients, because under-recognition of CVD in women
may contribute to a worse clinical outcome. This review will provide a synopsis of
available evidence on gender-based differences in the initial presentation, patho-
physiology and clinical outcomes of women affected by CVD.
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differences in therapeutic response [3,7]. For example,
women experience more bleeding than men regardless of
whether they are treated with GP IIb/IIIa inhibitors,
most likely because of frequent excess dosing in women
[8].
In addition, despite many important studies over the
past two decades have helped develop accurate clinical
tests, risk factors, preventive interventions and effective
therapies for CVD, the majority have either excluded
women entirely or included only limited numbers of
women and minorities. Thus, much of the evidence
supporting contemporary recommendations for testing,
prevention and treatment of CVD in women is extra-
polated from studies conducted predominantly on
middle-aged men [9]. Applying the findings of studies
on male cohorts for the management of CVD in women
may be inappropriate, because the symptoms of CVD,
natural history and response to therapy are different in
men and women [9,10].
Only recently, significant sex-related differences in
prevalence, presentation, management and outcomes of
CVD have been evaluated and discovered [2].
This review will briefly summarize gender-related
differences in clinical presentation of several CVD,
focusing at the same time on pathophysiologic explana-
tion of such differences compared to men population.
Knowing such gender differences may facilitate a rapid
identification of cardiac warning signs and symptoms in
health care givers promoting and facilitating the entry of
women into the health care system for a better and faster
treatment that can ultimately save a women’s life.
G E N D E R - R E L A T E D R I S K F A C T O R
D I F F E R E N C E S
Guidelines emphasize the importance of recognizing the
full spectrum of CVD and thus classify women as being at
high risk, intermediate risk, lower risk and optimal risk
[11].
New findings support the concept of a multifactorial
model, in which sex hormones interact with traditional
and conditional risk markers, leading to an increase in
the functional expression of atherosclerotic plaque
deposition or vascular or metabolic alterations resulting
in worsening outcomes for women [6]. Furthermore,
whereas the major cardiovascular risk factors are the
same in both sexes, gender-specific differences are noted
[12,13], and these differences are related to different
outcome. There is also substantial gender-related vari-
ability in the prevalence and outcome associated with
traditional cardiac risk factors (Table I). That is, although
overall rates of hypertension and smoking are higher in
men, elderly hypertensive women and young female
smokers are prominent at-risk subsets [14].
Population studies have noted that total cholesterol
measurements are higher in men until the fifth decade of
life but, beyond this age, women have greater values [2].
Furthermore, gender differences in high-density lipopro-
tein (HDL) values diminish with advancing age. Women
typically experience a relatively mild decline in HDL
cholesterol at the time of menopause [14,15]. In a
comprehensive review of 25 population studies, Manolio
et al. [16] reported that HDL cholesterol inversely
predicted coronary artery disease (CAD) in younger
women and men as well as older (65 years) women.
Hypertriglyceridemia is also a more potent independent
risk factor for CVD in women when compared with men
[2]. A recent meta-analysis of 17 studies revealed that
the CAD relative risk for hypertriglyceridemia was
elevated 32% in men and 76% for women [17].
Although younger-aged diabetic women (i.e., <45 years)
have an equally low prevalence of atherosclerosis [18],
numerous studies have reported a significantly higher
cardiovascular mortality for diabetic women when
compared with diabetic men [19,20]. The latter is
probably related to the fact that premenopausal diabetes
eliminates the ‘female advantage’ of a predominately
Table I A Comparison of Gender Differences in Traditional Cardiac
Risk Factors. Modified from reference (2).
Men Women
Risk factor threshold values
Age threshold for › disease risk ‡45 ‡55
Family history of premature <55 <65
Coronary heart disease
HDL cholesterol <50 mg/dl
Population average values
Lipids
Total cholesterol › › for women after
age 50 years
HDL cholesterol ›
Prevalence rates
Hypertension ›
Smoking ›
Coronary disease or outcome risk
Triglycerides ›
Diabetes mellitus ›
Obesity (e.g., BMI ‡30 kg/m2) › ›
Central obesity (‡35 kg/m2) ›
HDL = high-density lipoprotein.
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lower CAD prevalence and outcome risk that exists for
the female population in general [19]. Notably, the age-
adjusted prevalence of CVD is nearly twofold higher in
diabetic versus nondiabetic women [2].
Finally, the role that novel CVD risk factors and
recently developed screening technologies (e.g., coronary
calcium scoring) should play in guiding preventive
interventions is as yet unclear. New-advent risk indica-
tors such as inflammatory markers (for instance high-
sensitivity C-reactive protein, IL-6, fibrinogen and acute
phase protein), retinal artery narrowing, coronary artery
calcification, endothelial dysfunction and anaemia are
therefore now being studied in women [21].
C O R O N A R Y A R T E R Y D I S E A S E ( C A D )
I N W O M E N
Coronary artery disease is still considered to be a male
disease, and it is likely to be under-diagnosed in women
who often reported symptoms different from men. There
are multidimensional factors such as psychosocial,
physiological, anatomical and biological factors that
contribute to different symptoms between men and
women [22]. For example, women have smaller coro-
nary artery lumens and less collateral circulation than
men, which may lead to an increase in ischaemia,
particularly during exertion or stress. In addition, the
prevalence of obstructive coronary disease is particularly
low in premenopausal women, whilst increases dramat-
ically for a woman after age 50 [14]. In approximately
60% of cases of hospital admission, the initial presenta-
tion of CAD in women is acute myocardial infarction or
sudden cardiac death and up to half of all women
presenting with an acute myocardial infarction report no
prior chest pain symptoms [6,14].
The higher mortality noted for younger women when
compared with age-matched men could be due the
higher frequency of plaque erosion when compared to
more plaque rupture in men [23–25] (Figure 1).
In an autopsy series, women also had a greater
frequency of distal microvascular embolization in the
setting of a fatal epicardial thrombosis when compared to
men, independently of the type of thrombus or presence
of necrosis [26].
Another cause of acute myocardial infarction and
sudden death in women is spontaneous coronary artery
dissection. About 80% of the cases occurred in women,
in absence of coronary atherosclerosis, and more than
25% of these usually occur in the peripartum period
[27,28].
The dissection can involve every coronary artery, but
in women it frequently involves the left anterior
descending coronary artery, whereas in men the right
coronary artery is more frequently involved [28].
After sudden cardiac death, the most common pre-
sentation of obstructive CAD for women is atypical
symptoms such as back pain, dyspnoea, indigestion,
nausea/vomiting and weakness [12]. Frequently women
reported pain in the jaw and neck [22] and describe their
symptoms as more anguished and frightening (emo-
tional component) compared with men [29] (Table II).
Furthermore, women had more acute than prodromal
symptoms. The most frequent prodromal symptoms
reported up to 1 month before the onset of AMI were
unusual fatigue (70.7%), sleep disturbance (47.8%) and
shortness of breath (42.1%) [30]. In this context, a small
Figure 1 Gender differences in plaque morphologic features in an
autoptic series of patients who died for sudden cardiac death.
Modified from reference (25). SCD, sudden cardiac death;
Th, thrombus.
Table II Signs and symptoms of coronary heart disease (adapted
from the Harvard Medical School website—http://www.harvard.
health.edu).
Traditional heart attack warning signs
Pressure, burning, squeezing in the centre of the chest
Discomfort in one or both arms, shoulders, neck, jaw, stomach or back
Shortness of breath
Fatigue, cold sweat, nausea, weakness
Symptoms of coronary heart disease can differ in women
Pain in upper back, jaw or neck
Shortness of breath
Flu-like symptoms: nausea or vomiting, cold sweats
Fatigue or weakness
Feelings of anxiety, loss of appetite, discomfort
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proportion of patients (about 16%) with acute coronary
syndrome seek medical assistance for prodromal symp-
toms in the 90 days before the event. Seeking treatment
for these symptoms is associated with improved survival
in women but not in men, because prodromes were
associated with improved 1-year survival for women but
not for men [31].
At the time of first experience of a myocardial
infarction, women are often 7–10 years older and more
likely to have diabetes mellitus or heart failure (HF) than
men [32]. Particularly, diabetes is an independent
predictor of ‘atypical’ presentation of acute myocardial
infarction in women [33]. This atypical presentation of
CAD causes a delay in diagnosis and treatment in
women [34,35] and may lead to worse outcomes
characterized by increased hospital morbidity, higher
mortality and fewer evidence-based therapies, including
revascularization, anticoagulation, b-blockade, statins
and antiplatelet agents [36]. As demonstrated by the
Global registry of Acute Coronary Events (GREECS)
study, patients with ST-segment elevation myocardial
infarction were less likely to receive percutaneous
coronary intervention or fibrinolysis if their symptoms
were atypical [34]. Furthermore, chest pain typical for
angina pectoris is less likely to be associated with
obstructive epicardial CAD in women than in men [2].
However, in the presence of obstructive coronary
disease, women have an overall worse prognosis than
men, conditioning by the acuity of presentation and the
degree of comorbidity [37].
Despite women with chest pain in the absence of CAD
are at low risk for adverse cardiac events, a majority
continue to have symptoms that contribute to a poor
quality of life and consumption of large amounts of
health care resources because of repeated evaluations
and hospitalizations [38,39]. Many of these women are
diagnosed with ‘noncardiac’ chest pain. An alternative
mechanism for their symptoms, present in approximately
one-half of women with chest pain in the absence of
angiographically documented obstructive CAD, could be
a coronary microvascular dysfunction [40]. Differentia-
tion between these mechanisms of chest pain is impor-
tant, because ‘noncardiac’ chest pain is not associated
with cardiovascular sequelae and may require further
medical evaluation and treatment. By contrast, Syn-
drome X, which is thought to be caused by microvas-
cular dysfunction, is associated with inducible metabolic
ischaemia and can be treated by improving microvascu-
lar vasomotor tone with oral L-arginine, a precursor to
vascular nitric oxide, and oestrogen [40].
H E A R T F A I L U R E I N W O M E N
Data from the Framingham study suggest that the
lifetime risk of developing HF is about 20% for both men
and women [41]. There are differences between men and
women in clinical presentation, aetiology, treatment and
outcome in HF, and these differences lead to different
outcome. For example, women receive less life-prolong-
ing treatment (ACE-I, beta-blockers and spironolactone)
than men, in the presence of normal left ventricular
function, whilst there no difference if aetiology of HF is
CAD [42].
Typically, female patients with HF are older than
males and more likely to be hypertensive and diabetic
[43,44]. Usually, women tend to have better preserved
systolic function, a lower prevalence of ischaemic aeti-
ology and are less likely to have a history of prior MI
[43]. In fact, they are less likely to have CAD, but more
likely than men to have hypertension and valvular
disease as the underlying aetiology.
Some studies showed that women with chronic HF
have a better age-adjusted survival rate than men with
the same condition [45,46]. This is because of the fact
that women get underlying CVD at older age and they
have different aetiology of HF. Such survival data are
also confirmed in decompensated HF and in patients
referred to cardiac transplantation. In fact, women with
nonischaemic cardiomyopathy presented a better sur-
vival than men, irrespective of baseline characteristics,
while there was no advantage in presence of ischaemic
cause [47].
A peculiar type of left ventricular dysfunction and HF
typical in women is Takotsubo cardiomyopathy. This
disease is characterized by a left ventricular dysfunction,
electrocardiographic changes like an acute myocardial
infarction and release of cardiac biomarkers, in the
absence of obstructive coronary disease [48]. The left
ventricular dysfunction is usually reversible and it
improves within weeks, despite a dramatic clinical
presentation with substantial risk of complications in
the acute setting. The aetiology of Takotsubo has not
been clearly established. Many mechanisms have been
postulated to explain the pathophysiology, as catecol-
amine-mediated cardiotoxicity, multivessels coronary
vasospasm and abnormalities in coronary microvascular
function [49]. Many studies showed a marked gender
difference, because it is typically observed in postmeno-
pausal women [49] with the highest frequency of
occurrence between the seventh and eighth decade of
life [50].
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The reason for the much more common occurrence in
postmenopausal women is unclear. This disease is often
triggered by an emotionally stress or physical stress and
it is known that men and women have different response
to emotional stress [51].
Probably, it depends on the influence of sex hormones
on the sympathetic neurohormonal axis and on coro-
nary vasoreactivity [52]. Also menopause has been
associated with endothelial dysfunction in response to
reduced oestrogen levels [53]. This might add to the
effect that mental stress exerts directly on endothelium
[54].
A R R H Y T H M I A S I N W O M E N
It has been demonstrated that women have higher heart
rates at rest and longer corrected QT intervals than men,
probably due to differences in exercise tolerance, auto-
nomic modulation and intrinsic properties of the sinus
node [55]. After achieving autonomic blockade with
propanolol and atropine, Burke et al. [56] demonstrated
that this gender difference in heart rate persisted,
suggesting an intrinsic difference in the sinus node itself
as the cause. Furthermore, there are many differences in
incidence, prevalence, presentation and clinical course of
many arrhythmias, such as atrial fibrillation (AF) or
supraventricular arrhythmias (SVT) [57]. AF is the most
common arrhythmia in the adult population and gen-
erally its incidence increases with age both in men and
women, but it is more prevalent in men of all age groups.
In addition to gender difference in prevalence, there are
differences in outcomes and prognosis between men and
women with AF as well. Women with AF are more
symptomatic [57], older and have lower quality of life
and more co-morbidities than men [58]. Also they
present more likely a higher heart rate, longer episodes
and increase incidence of embolic strokes compared to
men [59]. Data from the Euro Heart Survey on Atrial
Fibrillation demonstrated that women are usually
treated less aggressively, with fewer cardioversions and
catheter ablations. In this study, albeit both genders
received anticoagulation therapy, women experienced a
significantly higher rate of stroke and major bleeding
events [58]. There are also differences in the incidence of
SVT: atrioventricular nodal re-entry tachycardia has a
2 : 1 female-to-male predominance, while accessory
pathways, including Wolf-Parkinson-White syndrome,
are twice as frequent in men [60]. Some study demon-
strated the evidence of hormonal effects on the triggers
and timing of SVT. It seems that many episodes and
symptomatic episodes are experienced by women during
the luteal phase of the menstrual cycle (when proges-
terone is elevated). Particularly, it is demonstrated a
cyclical variation in SVT inducibility during menstrua-
tion cycle. In fact, some patients were not inducible
during electrophysiologic studies performed at midcycle
but they became inducible when the studies repeated
during menstruation [61]. Also episodes of SVT increase
during pregnancy and during postpartum period [62].
The mechanisms for increase in this situation may be
related to hormonal effects, increased intravascular
volume and autonomic tone [63].
C O N C L U S I O N S
Several clinical observations clearly demonstrated the
importance of gender-specific differences in the clinical
presentation of CVD. For this reason, diagnosis and
treatment in women should be formulated from data on
women and not on data obtained from men. The ability
of knowing and recognizing gender differences in CVD
may facilitate a rapid identification of cardiac signs and
symptoms of warning and may avoid significant delays
in diagnosis and treatment in women. Continued efforts
are necessary to improve both knowledge and early
recognition of warning clinical presentation of CVD in
women to reduce the risk of mortality related to the
misleaded diagnosis that women are often still paying
because of the peculiar presentation related to their
gender.
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